Zayoryl 2 Tablet contains Glimepiride 2mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with inadequate response to diet and exercise alone. Glimepiride enhances insulin secretion in a glucose-dependent manner, minimizing the risk of hypoglycemia compared to older sulfonylureas. Zayoryl 2 is typically prescribed as part of a comprehensive diabetes management plan, including dietary modifications and physical activity. The tablet is administered once daily, preferably with breakfast, to optimize efficacy and reduce the likelihood of adverse effects. Common side effects may include hypoglycemia, dizziness, headache, and gastrointestinal disturbances such as nausea or abdominal discomfort. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Regular monitoring of blood glucose levels and periodic assessment of renal and hepatic function are recommended during therapy. Patient education on recognizing signs of hypoglycemia and adherence to prescribed dosing is essential for safe and effective treatment with Zayoryl 2 Tablet.